• Metabolite Binding and Regulation of TET2: Protocol Advances

  2026-06-09

  Zhang et al. introduce a protocol that combines biochemical assays with STD NMR spectroscopy to directly validate metabolite binding and regulatory effects on human TET2 dioxygenase. This methodological advance enables systematic identification of TET2 activators and inhibitors, deepening understanding of metabolic-epigenetic crosstalk and informing future studies of protein regulation and disease mechanisms.

• Oltipraz: Optimizing Nrf2-Driven Chemoprevention Workflows

  2026-06-09

  Oltipraz, a potent 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, empowers next-generation chemoprevention and MASLD research by precisely activating the Nrf2 pathway and modulating autophagy and ferroptosis. This guide translates experimental insights and recent peer-reviewed innovations into robust, troubleshooting-ready protocols for advanced cellular detoxification studies.

• EZ Cap™ Cas9 mRNA (m1Ψ): Precision Genome Editing Enhanced

  2026-06-08

  EZ Cap™ Cas9 mRNA (m1Ψ) empowers researchers with a Cap1-structured, m1Ψ-modified mRNA that drives efficient, low-immunogenicity CRISPR-Cas9 genome editing. This article maps advanced workflows, troubleshooting strategies, and cutting-edge assay options to maximize editing specificity and reproducibility in mammalian systems.

• RWJ 67657 (JNJ-3026582): Precision p38 MAPK Inhibition in In

  2026-06-08

  RWJ 67657 (JNJ-3026582) stands out as a highly selective, orally active p38α/β MAP kinase inhibitor, enabling researchers to dissect cytokine-driven inflammatory mechanisms with unprecedented specificity. Its dual-action mechanism uniquely combines TNF-alpha suppression and enhanced kinase dephosphorylation, streamlining translational workflows and troubleshooting in preclinical inflammatory models.

• Harnessing MK-2206 to Decipher Metabolic Control in Osteogen

  2026-06-07

  This thought-leadership piece explores how MK-2206 dihydrochloride enables translational researchers to interrogate the metabolic underpinnings of bone formation, leveraging recent mechanistic insights into Wnt signaling, O-GlcNAcylation, and Akt regulation. The article bridges oncology and bone metabolism, highlighting protocol guidance and positioning APExBIO's MK-2206 as a strategic asset for advanced pathway research.

• Catalpol in Osteoporosis and Neuroprotection: Applied Protoc

  2026-06-06

  Catalpol, a multi-target iridoid glycoside, delivers validated efficacy in osteoporosis and neuroprotection research through unique pathway modulation. This guide translates cutting-edge findings and practical workflows into actionable protocols, troubleshooting insights, and strategic experimental setups for disease model researchers.

• VE-822 ATR Inhibitor: Enhancing Sensitization in PDAC Resear

  2026-06-05

  VE-822 is a highly potent ATR inhibitor that enables precise DNA damage response modulation, particularly in pancreatic ductal adenocarcinoma workflows. This article delivers actionable protocol enhancements, troubleshooting strategies, and insights from the latest studies to maximize experimental outcomes with VE-822.

• Rotigotine Hydrochloride for Dopaminergic Signaling Research

  2026-06-05

  Rotigotine hydrochloride, a potent dopamine D2/D3 receptor agonist, is redefining experimental options in Parkinson’s disease and neurodegenerative research. This article details stepwise protocols, data-driven troubleshooting, and practical enhancements, drawing on the latest translational findings and APExBIO’s trusted supply chain.

• Benzyl Alcohol Mitigates Angiotensin II-Induced Vascular and

  2026-06-04

  This study identifies benzyl alcohol as a metabolomics-derived intervention that significantly reduces Angiotensin II-induced vascular remodeling and renal dysfunction in a mouse model. The findings provide mechanistic insight into pediatric hypertension pathology and highlight a novel avenue for therapeutic modulation of Ang II signaling in vascular and renal injury.

• Dopamine–H2S Axis and Dual Mitophagy in Ischemia–Reperfusion

  2026-06-04

  This study reveals that an enriched environment (EE) mitigates cerebral ischemia–reperfusion injury by activating dual mitophagy pathways via the dopamine–H2S axis. These findings highlight a neuroprotective cascade involving mitochondrial quality control, offering novel mechanistic insights and therapeutic targets for stroke intervention.

• Y-27632 Dihydrochloride: Precision ROCK Inhibition in Cellul

  2026-06-03

  Y-27632 dihydrochloride is revolutionizing in vitro research through its selective ROCK inhibition, streamlining workflows from stem cell viability to neuro-epithelial co-cultures. This article details optimized protocols, highlights data-driven troubleshooting, and translates innovations from a landmark microfluidic assay study.

• Spectral Cytometry Unveils Ruxolitinib’s Immune Effects in M

  2026-06-03

  This study introduces a 46-color spectral flow cytometry panel to deeply profile immune responses in murine sarcoma, revealing that Ruxolitinib combined with oncolytic HSV expands CD4 T cell and germinal center B cell populations. The findings highlight new dimensions of immunomodulation relevant to myeloproliferative disorder research and tumor immunotherapy.

• Fingolimod (FTY720): Translational Workflows in CAR-T-Mimicr

  2026-06-02

  Fingolimod (FTY720) powers next-generation immunomodulation by bridging lymphocyte trafficking control and neuroprotection, with unique advantages for in vivo CAR-T-mimicking cell workflows. This article delivers actionable experimental parameters, troubleshooting, and strategic insights for leveraging Fingolimod in complex immuno-oncology protocols.

• Ethacridine Lactate Monohydrate: Antiseptic Precision in Sup

  2026-06-02

  Explore how Ethacridine lactate monohydrate enables rigorous microbial control in advanced super-enhancer and epithelial lineage research. This article uncovers the molecular rationale, protocol optimization, and new insights distinct from existing resources.

• Topotecan’s Mechanism and Clinical Impact: Insights for Onco

  2026-06-01

  The reference study provides a comprehensive review of topotecan, a water-soluble topoisomerase I inhibitor with a distinct mechanism of inducing DNA damage and apoptosis in cancer cells. Its pharmacological profile, clinical efficacy, and toxicity patterns highlight both its promise and limitations, informing protocol design and combination strategies in cancer research.

448 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page